Efficacy and safety of Amomum villosum extracts in obese adults: A randomized, double-blind, placebo-controlled trial

被引:1
|
作者
Lee, Jung-Han [1 ]
Kim, Ha-Rim [2 ,3 ]
Antonisamy, Paulrayer [2 ,3 ]
Kim, Ye-Seul [2 ,3 ]
Ryu, Do-Gon [2 ]
Lee, Guemsan [4 ]
Kwon, Kang-Beom [2 ,3 ,5 ,6 ]
机构
[1] Wonkwang Univ, Coll Korean Med, Dept Korean Med Rehabil, Iksan, Jeonbuk, South Korea
[2] Wonkwang Univ, Coll Korean Med, Dept Physiol, Iksan, Jeonbuk, South Korea
[3] Ilwonbio Co Ltd, Iksan, Jeonbuk, South Korea
[4] Wonkwang Univ, Coll Korean Med, Dept Herbol, Iksan, Jeonbuk, South Korea
[5] Ilwonbio Co Ltd, 460 Iksandaero, Iksan 54538, Jeonbuk, South Korea
[6] Wonkwang Univ, Dept Physiol, Coll Korean Med, 460 Iksandaero, Iksan 54538, South Korea
关键词
Amomum villosum; Body weight; Obesity; Visceral adipose tissue; Randomized controlled trial; BODY-WEIGHT; WAIST CIRCUMFERENCE; FAT ACCUMULATION; OVERWEIGHT; INDIVIDUALS; LEPTIN;
D O I
10.1016/j.jksus.2023.102580
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: This study aimed to assess how well Amomum villosum water extract (AVE) assisted over-weight to moderately obese people in losing weight. Methods: Eighty participants were chosen at random for the AVE group or the placebo group for this experiment. Subjects were given two tablets of the test substance after their two consistent meals daily for 12 weeks. At the starting and completion of the experiment, measurements of body mass index (BMI), body weight, percent body fat, body fat mass, visceral adipose tissue (VAT), lean body mass, subcuta-neous adipose tissue (SAT), percent VAT (%), and percent SAT (%) were taken. Before and after the study, blood samples were obtained for safety laboratory parameters. Results: After taking the products for 12 weeks, the AVE group lost considerably more weight than the placebo group (-2.04 +/- 3.04 kg vs-0.30 +/- 2.88 kg, respectively; P < 0.014). Additionally, the AVE group showed reduction in body fat mass of-1393.63 +/- 2268.80 g as compared to the placebo group's reduc-tion of 51.67 +/- 2111.05 g (P < 0.006). In comparison to the placebo group, VAT and SAT weight signifi-cantly lowered in the AVE group. There were no negative effects associated with AVE consumption. Before and after AVE administration, 31 of 38 participants (81.6 %) lost weight. Similarly, 26 of 38 mem-bers (68.4 %) lost weight and body fat mass before and after AVE administration. Conclusions: These results suggest that AVE might be a reliable and secure weight regulation. WKUIOMH-IRB-2020-01 is the registration number for this trial. (c) 2023 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [1] Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial
    Park, Sunju
    Nahmkoong, Won
    Cheon, ChunHoo
    Park, Jeong-Su
    Jang, Bo-Hyoung
    Shin, Yongcheol
    Kim, Kyung-Soo
    Go, Hoyeon
    Song, Yun-Kyung
    Ko, Seong-Gyu
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [2] Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double-blind, placebo-controlled trial
    Xiang, Yingying
    Shen, Lixuan
    Xue, Yingying
    Wang, Ziwei
    Zhou, Ruonan
    Cao, Yue
    Zhu, Ziwei
    Xu, Pingyuan
    Yu, Xizhong
    Fang, Penghua
    Shang, Wenbin
    DIABETES OBESITY & METABOLISM, 2024,
  • [3] Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial
    Campillo, Jeremy T.
    Bikita, Paul
    Hemilembolo, Marlhand
    Louya, Frederic
    Missamou, Francois
    Pion, Sebastien D. S.
    Boussinesq, Michel
    Chesnais, CedricB
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : 19 - 27
  • [4] Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial
    Garbutt, James C.
    Kampov-Polevoy, Alexei B.
    Gallop, Robert
    Kalka-Juhl, Linda
    Flannery, Barbara A.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (11) : 1849 - 1857
  • [5] Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial
    Maria, Morais-Socorro
    Alvaro, Cavalcanti Maciel
    Rand, Martins
    Paulo, Neto Francisco
    Adriana, Rezende
    George, Azevedo
    Maria, Almeida
    GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (06) : 483 - 487
  • [6] Efficacy and Safety of Desloratadine in Adults with Chronic Idiopathic UrticariaA Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
    Jean-Paul Ortonne
    Jean-Jacques Grob
    Pascal Auquier
    Isabelle Dreyfus
    American Journal of Clinical Dermatology, 2007, 8 : 37 - 42
  • [7] Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria - A randomized, double-blind, placebo-controlled, multicenter trial
    Ortonne, Jean-Paul
    Grob, Jean-Jacques
    Auquier, Pascal
    Dreyfus, Isabelle
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2007, 8 (01) : 37 - 42
  • [8] Efficacy and Safety of Orlistat in People with Overweight/Obese and Hyperuricemia-Results of a Randomized, Double-Blind, Placebo-Controlled Trial
    Liu, Shuang
    Qu, Shen
    Chen, Haibing
    DIABETES, 2024, 73
  • [9] Randomized, double-blind, placebo-controlled study of efficacy and safety of secukinumab to treat adults with ichthyoses
    Lefferdink, R. L.
    Chima, M.
    Ibler, E.
    Pavel, A. B.
    Kim, H.
    Wu, B.
    Abu-Zayed, H.
    Rangel, S.
    Wu, J.
    Zumpf, K.
    Jackson, K.
    Choate, K.
    Guttman-Yassky, E.
    Paller, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S74 - S74
  • [10] Efficacy and safety of Gelidium elegans intake on bowel symptoms in obese adults A 12-week randomized double-blind placebo-controlled trial
    Choi, Hyoung Il
    Cha, Jae Myung
    Jeong, In-Kyung
    Cho, In-Jin
    Yoon, Jin Young
    Kwak, Min Seob
    Jeon, Jung Won
    Kim, Soo Jin
    MEDICINE, 2019, 98 (17)